Can-Fite BioPharma Ltd. (CANF)

Can-Fite BioPharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	0.67	0.74	0.81	0.85	0.76
Revenue Growth (YoY)	-9.29%	-8.27%	-5.04%	11.80%	-62.45%
Gross Profit	0.67	0.74	0.81	0.85	0.76
Selling, General & Admin	3.05	2.96	3.14	3.85	2.95
Research & Development	5.76	5.98	7.76	9.85	11.95
Operating Expenses	8.8	8.94	10.91	13.7	14.9
Operating Income	-8.13	-8.2	-10.1	-12.84	-14.14
Interest Expense	-	-	-	-	-0.36
Interest & Investment Income	0.29	0.51	0.22	0.02	0.04
Currency Exchange Gain (Loss)	-0.01	0.06	-0.05	0.06	0.03
Other Non Operating Income (Expenses)	-0.01	-0.01	-0.02	-0.02	-0.02
EBT Excluding Unusual Items	-7.87	-7.65	-9.94	-12.78	-14.45
Gain (Loss) on Sale of Investments	-0.01	0.01	-0.23	0.16	0.01
Pretax Income	-7.88	-7.63	-10.17	-12.62	-14.44
Earnings From Continuing Operations	-7.88	-7.63	-10.17	-12.62	-14.44
Net Income	-7.88	-7.63	-10.17	-12.62	-14.44
Preferred Dividends & Other Adjustments	-	-	-	2.59	0.72
Net Income to Common	-7.88	-7.63	-10.17	-15.21	-15.16
Shares Outstanding (Basic)	2,176	1,278	816	553	358
Shares Outstanding (Diluted)	2,176	1,278	816	553	358
Shares Change (YoY)	70.22%	56.71%	47.49%	54.31%	317.19%
EPS (Basic)	-0.00	-0.01	-0.01	-0.03	-0.04
EPS (Diluted)	-0.00	-0.01	-0.01	-0.03	-0.04
Free Cash Flow	-7.64	-8.44	-10.81	-9.87	-12.09
Free Cash Flow Per Share	-0.00	-0.01	-0.01	-0.02	-0.03
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1206.23%	-1102.96%	-1246.42%	-1505.51%	-1853.08%
Profit Margin	-1169.14%	-1027.46%	-1255.93%	-1782.53%	-1986.63%
Free Cash Flow Margin	-1133.83%	-1136.20%	-1334.57%	-1156.98%	-1584.40%
EBITDA	-8.12	-8.18	-10.08	-12.83	-14.13
D&A For EBITDA	0.01	0.02	0.01	0.01	0.01
EBIT	-8.13	-8.2	-10.1	-12.84	-14.14

Updated Aug 29, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q